Jade Therapeutics, EyeGate deal

EyeGate acquired fellow ophthalmic company Jade for up to $5.4 million. EyeGate will pay up to $300,000 in Jade liabilities and issue 765,728 EyeGate shares valued at $2.9 million based on EyeGate’s close of $3.83 on March 4, before the deal was announced. Jade is eligible for a $2.2 million milestone payment upon FDA approval of a Jade product. ...